



De.mem Limited (ASX:DEM)

Capital Raising Presentation

28 July 2022

This presentation has been prepared by De.mem Limited and its related entities (the “Company”). It does not purport to contain all the information that a prospective investor may require in connection with any potential investment in the Company. You should not treat the contents of this presentation, or any information provided in connection with it, as financial advice, financial product advice or advice relating to legal, taxation or investment matters.

No representation or warranty (whether express or implied) is made by the Company or any of its officers, advisers, agents or employees as to the accuracy, completeness or reasonableness of the information, statements, opinions or matters (express or implied) arising out of, contained in or derived from this presentation or provided in connection with it, or any omission from this presentation, nor as to the attainability of any estimates, forecasts or projections set out in this presentation. This presentation is provided expressly on the basis that you will carry out your own independent inquiries into the matters contained in the presentation and make your own independent decisions about the affairs, financial position or prospects of the Company. The Company reserves the right to update, amend or supplement the information at any time in its absolute discretion (without incurring any obligation to do so). Neither the Company, nor its related bodies corporate, officers, their advisers, agents and employees accept any responsibility or liability to you or to any other person or entity arising out of this presentation including pursuant to the general law (whether for negligence, under statute or otherwise), or under the Australian Securities and Investments Commission Act 2001, Corporations Act 2001, Competition and Consumer Act 2010 or any corresponding provision of any Australian state or territory legislation (or the law of any similar legislation in any other jurisdiction), or similar provision under any applicable law. Any such responsibility or liability is, to the maximum extent permitted by law, expressly disclaimed and excluded. Nothing in this material should be construed as either an offer to sell or a solicitation of an offer to buy or sell securities. It does not include all available information and should not be used in isolation as a basis to invest in the Company.

Future Matters | This presentation contains reference to certain intentions, expectations, future plans, strategy, revenue forecasts and prospects of the Company. Those intentions, expectations, future plans, strategy, revenue forecasts and prospects may or may not be achieved and may be forward looking statements. They are based on certain assumptions, which may not be met or on which views may differ and may be affected by known and unknown risks. The performance and operations of the Company may be influenced by a number of factors, many of which are outside the control of the Company. No representation or warranty, express or implied, is made by the Company, or any of its directors, officers, employees, advisers or agents that any intentions, expectations or plans will be achieved either totally or partially or that any particular rate of return will be achieved. Given the risks and uncertainties that may cause the Company's actual future results, performance or achievements to be materially different from those expected, planned or intended, recipients should not place undue reliance on these intentions, expectations, future plans, strategy, revenue forecasts and prospects. The Company does not warrant or represent that the actual results, performance or achievements will be as expected, planned or intended.

US Disclosure | This document does not constitute any part of any offer to sell, or the solicitation of an offer to buy, any securities in the United States or to, or for the account or benefit of any “US person” as defined in Regulation S under the US Securities Act of 1993 (“Securities Act”). The Company's shares have not been, and will not be, registered under the Securities Act or the securities laws of any state or other jurisdiction of the United States, and may not be offered or sold in the United States or to any US person without being so registered or pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and other applicable US state securities laws. The distribution of this document in the United States and elsewhere outside Australia may be restricted by law. Persons who come into possession of this document should observe any such restrictions as any non-compliance could contravene applicable securities laws. Please refer to the section of this document headed “International Selling Restrictions” for more information.

All figures included in this presentation are in AUD\$ unless otherwise stated. Assumed exchange rate of AUD\$1:USD\$0.75

This document does not constitute an offer of new ordinary shares ("New Shares") of the Company in any jurisdiction in which it would be unlawful. In particular, this document may not be distributed to any person, and the New Shares may not be offered or sold, in any country outside Australia except to the extent permitted below.

Germany

This document has not been, and will not be, registered with or approved by any securities regulator in Germany or elsewhere in the European Union. Accordingly, this document may not be made available, nor may the New Shares be offered for sale, in Germany except in circumstances that do not require a prospectus under Article 1(4) of Regulation (EU) 2017/1129 of the European Parliament and the Council of the European Union (the "Prospectus Regulation").

In accordance with Article 1(4)(a) of the Prospectus Regulation, an offer of New Shares in Germany is limited to persons who are "qualified investors" (as defined in Article 2(e) of the Prospectus Regulation).

Hong Kong

WARNING: This document has not been, and will not be, registered as a prospectus under the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap. 32) of Hong Kong, nor has it been authorised by the Securities and Futures Commission in Hong Kong pursuant to the Securities and Futures Ordinance (Cap. 571) of the Laws of Hong Kong (the "SFO"). Accordingly, this document may not be distributed, and the New Shares may not be offered or sold, in Hong Kong other than to "professional investors" (as defined in the SFO and any rules made under that ordinance).

No advertisement, invitation or document relating to the New Shares has been or will be issued, or has been or will be in the possession of any person for the purpose of issue, in Hong Kong or elsewhere that is directed at, or the contents of which are likely to be accessed or read by, the public of Hong Kong (except if permitted to do so under the securities laws of Hong Kong) other than with respect to New Shares that are or are intended to be disposed of only to persons outside Hong Kong or only to professional investors. No person allotted New Shares may sell, or offer to sell, such securities in circumstances that amount to an offer to the public in Hong Kong within six months following the date of issue of such securities.

The contents of this document have not been reviewed by any Hong Kong regulatory authority. You are advised to exercise caution in relation to the offer. If you are in doubt about any contents of this document, you should obtain independent professional advice.

New Zealand

This document has not been registered, filed with or approved by any New Zealand regulatory authority under the Financial Markets Conduct Act 2013 (the "FMC Act").

The New Shares are not being offered or sold in New Zealand (or allotted with a view to being offered for sale in New Zealand) other than to a person who:

- is an investment business within the meaning of clause 37 of Schedule 1 of the FMC Act;
- meets the investment activity criteria specified in clause 38 of Schedule 1 of the FMC Act;
- is large within the meaning of clause 39 of Schedule 1 of the FMC Act;
- is a government agency within the meaning of clause 40 of Schedule 1 of the FMC Act; or
- is an eligible investor within the meaning of clause 41 of Schedule 1 of the FMC Act.

Singapore

This document and any other materials relating to the New Shares have not been, and will not be, lodged or registered as a prospectus in Singapore with the Monetary Authority of Singapore. Accordingly, this document and any other document or materials in connection with the offer or sale, or invitation for subscription or purchase, of New Shares, may not be issued, circulated or distributed, nor may the New Shares be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore except pursuant to and in accordance with exemptions in Subdivision (4) Division 1, Part 13 of the Securities and Futures Act 2001 of Singapore (the "SFA") or another exemption under the SFA.

This document has been given to you on the basis that you are an "institutional investor" or an "accredited investor" (as such terms are defined in the SFA). If you are not such an investor, please return this document immediately. You may not forward or circulate this document to any other person in Singapore.

Any offer is not made to you with a view to the New Shares being subsequently offered for sale to any other party in Singapore. On-sale restrictions in Singapore may be applicable to investors who acquire New Shares. As such, investors are advised to acquaint themselves with the SFA provisions relating to resale restrictions in Singapore and comply accordingly.

Switzerland

The New Shares may not be publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange or on any other stock exchange or regulated trading facility in Switzerland. Neither this document nor any other offering or marketing material relating to the New Shares constitutes a prospectus or a similar notice, as such terms are understood under art. 35 of the Swiss Financial Services Act or the listing rules of any stock exchange or regulated trading facility in Switzerland.

No offering or marketing material relating to the New Shares has been, nor will be, filed with or approved by any Swiss regulatory authority or authorised review body. In particular, this document will not be filed with, and the offer of New Shares will not be supervised by, the Swiss Financial Market Supervisory Authority (FINMA).

Neither this document nor any other offering or marketing material relating to the New Shares may be publicly distributed or otherwise made publicly available in Switzerland. The New Shares will only be offered to investors who qualify as "professional clients" (as defined in the Swiss Financial Services Act). This document is personal to the recipient and not for general circulation in Switzerland.

De.mem provides innovative products and solutions for decentralised water treatment including hollow fibre membrane water treatment systems & associated specialty chemicals



Technology Driven Competitive Advantage & Customer Value Proposition

Unique hollow fibre membranes result in simplified installations & operations which enhance water and energy efficiencies which ultimately provides customers with a unique value proposition.



~85% Recurring Revenue Base (H1 CY2022)

Expected recurring revenue and/or cash receipts of \$17.5-20m in CY22 reflecting growth of ~28-46% on CY21. Revenues are inherently sticky - never lost a material contract to a competitor in the BOO or O&M segments.



13 Successive Quarters of Growth – Break Even in Sight

23% in cash receipts growth in H1 2022 vs PCP, to approx. \$10.7m, with quarterly EBITDA break even expected by H1 CY23. \$4.0M¹ of available cash/deposits at 30 June 2022, providing ample runway to support future growth prospects.



Blue Chip Customer Base

Multinational customer base provides a foundation for growth via land & expand and cross sell opportunities.

RioTinto Acciona Coca-Cola Pilbara Minerals aql INOVARIS Alcoa MULPHA KRONES COSTA Givaudan



ESG Drivers are Accelerating

ESG pressures are growing & driving the adoption of wastewater solutions across key target markets making De.mem's products more attractive to potential customers.



Favourable Market Dynamics – Highly Fragmented, Large Addressable Market

Competitors are focused on niche segments with limited technical, financial and organisational capabilities. Domestic TAM of A\$2.3bn with global TAM expected to reach US\$39bn by 2026 (see slide 7).



Opportunistic Acquisition Strategy

Four disciplined acquisitions completed which have expanded the service offering, built a presence in key markets and enabled cross selling opportunities.

¹Excludes proceeds from the capital raising


DEM is pleased to report a strong result for the June 2022 Quarter

Key Highlights


- **Best ever June quarter** in Company history with approx. \$5.6m in cash receipts and **continuing growth momentum** with 13 successive quarters of cash receipts growth
- **High-margin recurring revenue segments** approx. 85% of total cash receipts in H1 CY2022 (up from 38% in CY2018)
- **Strong outlook for recurring revenue growth in CY2022**; recurring cash receipts forecast increased to \$17.5 - 20m for CY2022 (implied growth of 28% - 46% vs CY2021 recurring revenue)
- **Strategic acquisition of Stevco Seals & Pumps Victoria Pty Ltd completed** during the quarter, adding ~\$330,000 of EBITDA per annum and providing further cross selling opportunities
- **Signed a new 3-year service contract with Rio Tinto**, to manage the potable water and sewage treatment plants at the Amrun mine in Queensland, Australia
- **Signed partnership agreement** with Puraify Clean Technologies for the commercialisation of DEM's Graphene Oxide enhanced ("GO") membrane technology
- **Appointment of Danny Conlon** as non-executive director, former CEO & Managing Director of Veolia Australia & New Zealand

*"Strategic focus shifting towards **profitability**, with quarterly operating cash flow and/or EBITDA break even targeted by H1 CY 2023"*

CASH RECEIPTS GROWTH SINCE CY2019 – STRONG START TO CY2022 (IN A\$ MILLION)



RECURRING CASH RECEIPTS VS. TOTAL CASH RECEIPTS



LARGE ADDRESSABLE MARKET: STRONG REGULATORY TAILWINDS

ESG pressures are growing & driving the adoption of wastewater solutions and services. De.mem is well positioned to capitalise on these as a provider of water treatment solutions

Drivers of Adoption

Treated wastewater being embraced as a sustainable alternative to fresh water

Growing cost of compliance, increased regulatory & social governance pressures

Water is a scarce resource which is fundamental to certain industries

Increased recognition of requirement to invest in ESG & regenerative practises



Significant Addressable Market

A\$2.3bn

Total Addressable Market in Australia

Decentralised wastewater systems
A\$300m p.a.¹

Pumps equipment market
>A\$1bn p.a.²

Water treatment chemicals
>A\$1bn p.a.³

US\$39bn

Global market for decentralised water treatment by 2026⁴

Sources:


(1) Company estimates

(2) From the Australian Pump Industry Association website, April 2022

(3) RFDTV, Australian Water Treatment Chemicals Market Size in 2018, 29/11/2021

(4) Research & Markets, "Decentralized Water Treatment Market – Global Outlook and Forecast 2021-26", 24/9.2021

Principle of Hollow Fibre Membrane Filtration



- De.mem's membranes are a microporous structure, whereby the pore size within the membrane determines which contaminants can be removed.
- Membrane sizes span across nano, ultra and micro with varying pore sizes. Contaminants that can be removed are in Appendix 1.

Technology results in lower CAPEX & operating costs driven by the following:

- **Less Power Required:** Typically operates under 1-2 bar pressure, which can reduce energy consumption by up to 70% vs. a standard reverse osmosis plant (where applicable)
- **Less Harmful Chemicals Required:** Membrane can be operated in a simple, one-stage process, without additional pre-filtration resulting in less harmful and/or bulk chemicals
- **Ease of Use & Cleaning:** Simple backwash cleaning process results in reduced chemical usage, less maintenance requirements and longer product life due to minimal membrane fouling
- **Lower Footprint:** Less space required for treatment plant due to membranes high throughput capabilities and ability to be containerized

Membrane Bundles



Membrane Modules



De.mem provides clients with a comprehensive water & waste water treatment offering. These divisions and services are highly complimentary and allow for cross selling opportunities



De.mem has a strong customer value proposition for clients driven by our technology and ability to deliver fully integrated solutions

Competitive Market Dynamics

- Highly fragmented market with large number of smaller competitors who have limited technical, financial & organizational capabilities
- Competitors typically focused on selling low margin, commodity type products with little differentiation
- Vast array of treatment technologies which are typically focused on niche segments of the market, translating to a smaller market opportunity
- Investment in R&D is rarely undertaken

DEM's Technology Advantage

A portfolio of advanced membrane technology for high value applications / requirements

Clear advantages over established technology: high efficiency, superior contaminant removal, simplified operations, reduced cost and footprint

"Next gen" membrane technology with superior characteristics over existing membrane tech

DEM's Business Model Advantage

"One stop shop" providing an opportunity to gain a larger share of client spend & assisting with winning and retaining customers

Broadly applicable solutions resulting in a larger market opportunity

Advanced technology, providing a "competitive edge", assisting with winning and retaining customers

Unique build own operate model offering which provides customers with a strong value proposition

De.mem has never lost a material* BOO or O&M contract once installed. These services are inherently very sticky



Contract with Mulpha / IHG Hospitality sector

- Supplied containerised seawater desalination plant for luxury resort in Australia in a \$3m project
- Designed & manufactured the plant utilising a De.mem membrane process
- Provides drinking water to the resort
- Service agreement (O&M) in place since 2020 with revenues of ~\$300k per annum
- 1,500,000 litres per day of water treated



Contract with Givaudan Food & Beverage

- Containerized industrial waste water treatment plant for food and beverage factory in Singapore
- Build, Own, Operate contract with value \$1.7m in revenues over 6 years, contract started 2021
- Deploying De.mem membranes
- Treats the waste water from facility to regulatory discharge standards
- 50,000 litres per day of waste water treated



Contract with Australian corporate Agricultural sector

- Containerized industrial waste water treatment plant for industrial site in South Australia
- Build, Own, Operate, Transfer contract with value of \$2m in revenues over 5 years, starting 2022
- Deploying De.mem membranes and chemicals
- Treats the waste water from facility to regulatory discharge standards
- 200,000 litres per day of waste water treated

*Material is defined as a contract with revenue above \$100k per annum.

De.mem has a high margin, specialty water treatment chemicals division. These products are used in conjunction with membranes, opening up substantial cross-sell opportunities

- All water treatment plants require some form of chemicals to ensure the system meets discharge requirements
- De.mem's hollow fibre membranes require small amounts of high-value speciality chemicals for cleaning and fouling control during operations
- De.mem manufactures non-commoditized speciality chemicals which are high value add and high margin including:
 - Scale and corrosion inhibitors
 - Process cleaning agents
 - Industrial cooling tower water treatment
 - Process aids (biocides, defoamers, viscosity modifiers etc)
 - Waste water treatment chemicals (coagulants & flocculants)
- Significant cross selling opportunity combining De.mem's membranes & water treatment products with specialty chemicals as these are all required by the customer at the same time



De.mem's Graphene-Oxide enhanced membrane allows for substantially increased throughput compared to a standard UF membrane. This is a game changing advancement

- Standard polymer Ultrafiltration membrane enhanced by the addition of Graphene Oxide nanoparticles.
- Developed in-house during a 24-month R&D process, allows for 20-40% more water flux (throughput of water volume) when compared with standard polymer membranes. Even higher flux can be achieved in certain applications.
- The increased flux allows for two key benefits to be attained:
 - **Reduced OPEX:** Ability to treat more water for same cost
 - **Reduced footprint:** Ability to produce a smaller membrane cartridge which will still treat the same amount of water
- Currently preparing for initial rollout of the technology as part of a domestic water filtration device (point of entry/use filtration)
- Lower operating costs and small footprint are valuable in domestic setting
- NSF certification process for drinking water usage has been initiated and results are expected in H2 2022
- **Announced commercial partnership with Purafy, Canada, to jointly enter the North American market (see ASX release dated 19 July 2022)**



Our customers typically have multiple sites and operations that require wastewater treatment & services. We are focused on growing with our customers through a land and expand strategy

Mining

- Potable/sewage treatment for mining camps
- Waste water
- Mining water supply

Rio Tinto



Monadelphous



Infrastructure

- Potable
- Sewage treatment
- Water treatment for industrial facilities



Food & Beverage

- Waste water
- Process water
- Ultrapure water
- Recycling




Other Industrial


- Industrial waste water
- Process water
- Ultrapure water
- Recycling



De.mem's growth model foresees expansion together with its multinational customer base “from site to site” – enabling an accelerating growth trajectory



Revenue Performance of DEM Acquisitions



- 4 acquisitions completed since 2019
- Strong acquisition track record of generating shareholder value through cross sell
- All acquisitions have stable, recurring revenues
- Bolt-on acquisitions as an option to further accelerate top line growth
- Recently completed Stevco acquisition expected to have material positive impact on CY22 numbers if integrated successfully like previous acquisitions


Business Name	Business Focus	Price Paid	Rationale & Cross Selling Opportunities
Capic Perth Based 2021	A supplier of high value add, high margin, speciality chemicals within mining services.	\$3.4m cash \$1.0m scrip	Provided De.mem with increased scale & geographic expansion into the strategically important WA market. Added complementary product range, blue-chip customer base and potential revenue cross-sell synergies.
Pumptech Tasmania Tasmanian Based 2019	Main product lines include membrane-based and other water / waste water treatment systems, as well as mechanical equipment.	\$0.9m cash \$0.15m scrip	Provided geographic expansion into Tasmania, further penetration of target verticals, product portfolio expansion, cross-sell opportunities, cost synergies and earnings accretion.
Geutec German Based 2019	Develops, manufactures and sells innovative chemicals-based products and solutions for waste water treatment to customers across Germany and Europe	\$0.92m cash (75% stake)	Provided platform for expansion into Europe, proprietary chemical range and synergistic membrane products. De.mem's existing customer base, expressed pre-existing demand for products sold by Geutec. Geutecs products were a key input for De.mem's membrane treatments.
Stevco Seals & Pumps Victorian Based 2022	Supplier of pumps, small water treatment equipment & maintenance services in Victoria.	\$1.25m cash \$0.25m scrip	Stevco's long term customer base also requires larger water treatment equipment, services and chemicals. This creates substantial potential for cross-selling of De.mem's advanced membrane-based water treatment solutions and its specialty chemicals range.

Visible path to achieving quarterly EBITDA breakeven by H1 CY2023 with a focus on growing recurring revenue base and increasing margins

\$ million (Dec year end)	CY19	CY20	% on PCP	CY21	% on PCP
Revenues	10.1	14.1	40%	18.1	28.3%
COGS	7.5	9.8	30%	12.1	23.4%
Gross Profit	2.6	4.3	65%	6.1	41.8%
EBITDA	(-3.2)	(-2.8)	13%	(-2.9)	-3.5%
Underlying EBITDA*	(-3.2)	(-3.1)	3.1%	(-2.2)	29%
Cash Balance	7.8	4.6	-41%	8.5	84%

Strong start to CY22 – H1 CY22 cash receipts up 23% on PCP (A\$ million)

Recurring revenues (A\$ million)



*Operating loss as per P&L adjusted for D&A, interest expense and one-off items such as Covid-19 subsidies and business acquisition cost (see the annual report for CY21)

TRACK RECORD OF REVENUE GROWTH

- Revenue of \$10.1m in CY19 to \$18.1m in CY21
- 23% in cash receipts growth in H1 2022 vs PCP, to approx. \$10.7m**
- 13 consecutive quarters of growth in cash receipts

RECURRING REVENUE GROWTH DRIVES MARGINS

- Recurring revenue segments accounted for ~85% of total revenues in CY21 up from 38% in CY18
- Expected recurring revenue of \$17.5 – 20m in CY22 reflecting growth of ~28 - 46% on CY21**
- Gross margins up from 19% in CY17 to 34% in CY21, increases expected as higher margin recurring revenue segments drive growth

PROFITABILITY & BREAK EVEN

- Visible path to quarterly EBITDA break even, targeting by H1 2023**
- Cash & term deposits of \$4.0m at 30 June 2022 (excluding proceeds from the capital raising)**
- Underlying EBITDA of -\$2.2m in CY21:
 - approx. \$1m investment into the Singapore subsidiary, which is predominantly undertaking membrane R&D
 - approx. \$1m investment in the scale up of the sales & marketing organization in Australia and Germany.

De.mem is driven by our impact on society. Our technology is pioneering a revolution in how we can better utilise our environments' limited resources in order to sustainably meet/exceed regulated ESG targets



Water Treatment & Reuse

- De.mem's membrane technology and treatment plants clean waste water, facilitate water discharge and water reuse/recycling
- Treated a total of 550 million litres of water under our BOO and O&M contracts across 15 sites in Australia and Singapore in Q1 CY2022
- Equivalent of ~220 Olympic sized swimming pools of waste water being turned safe for discharge and reuse



Less Power, Land & Chemicals

- De.mem's hollow fibre membrane technology is a sustainable solution. Environmental benefits:
- Up to a 70% reduction in power consumption compared to reverse osmosis
- Systems and plants have smaller foot prints translating to less land requirements
- Less chemicals are required to operate and maintain De.mem systems



Plastic Waste Reduction

- De.mem's domestic water filters are being actively used by customers to replace bottled drinking water
- Anticipated launch of new graphene oxide enhanced membranes lead to further uptake of De.mem's domestic filters
- More than 373 million plastic bottles are used in Australia per annum with only 36% being recycled



Cosimo Trimiglozzi
Non-Executive Director

30-year experience in the feed and food ingredients / flavours & fragrances industry

Former COO at Wild Flavors, and was a key member involved in the sale of the Company to ADM Group for approx. US\$2.5 billion

Previously, MD Asia for Givaudan, Switzerland



Bernd Dautel
Non-Executive Director

Director and Partner with New Asia Investments for the past decade

Previously MD of Wieland Asia/Pacific, growing the Asia-Pacific business from a small enterprise to generating more than SGD\$400 million in revenues, for one of the world's leading independent producers of semi-finished copper and copper alloy products



Andreas Kroell
CEO & Director

Previously Director and Partner of New Asia Investments, a Singapore-based technology investment firm, responsible for numerous investments in the water and industrial sectors

Experience at Nanostart AG, a German publicly listed nanotech-focused VC fund, and holding corporate finance roles with Deutsche Bank and Deloitte in Germany



Michael Edwards
Non-Executive Director

A Geologist and Economist with over 20 years of senior management experience in both the private and public sector

Currently Executive Chairman of Auroch Minerals (ASX:AOU) and Non-Executive Chairman of Greenstone Resources (ASX:GSR)



Danny Conlon
Non-Executive Director

CEO and Managing Director of Veolia for the Australia & New Zealand region from 2018-20, responsible for more than 4,000 employees and 240 locations across the region

With Veolia since 1998. Served as the Executive General Manager of Veolia's East Coast Operations in ANZ, prior to being the CEO



Stuart Carmichael
Non-Executive Director

Principal and Director at Ventnor specialising in corporate and financial advice to small cap ASX listed companies including capital raisings, IPO's, restructures and M&A

A Chartered Accountant with over 20 years' experience in the provision of corporate advisory services both within Australia and internationally



Market Data

ASX Code	DEM.ASX
Ordinary Shares (25 July 2022)	223.0m
Market capitalisation (25 July 2022)	\$41.25m
Options on Issue	7.11m
Cash plus term deposits (30 June 2022) ¹	\$4.0m
Last price (25 July 2022)	\$0.185
52 week high	\$0.31
52 week low	\$0.14

Major Shareholders

NA Singapore Early Stage Venture Fund	20%
Perennial Value Management	14%
New Asia Investments	5%
Pathfinder Asset Management	4%
Other Institutional Shareholders	2%
Board & Management Shareholding	2%

¹Excludes proceeds of the capital raising

Share Price Performance**DEM Relative to ASX Small Industrials Index**

Placement

- A\$3.0 million non-underwritten Placement of fully paid ordinary shares to Professional and Sophisticated investors (the “**Placement**” or “**Offer**”) under the Company’s existing placement capacity under ASX Listing Rules 7.1¹
 - Offer price of A\$0.14 per share via the issue of approximately 21.4 million New Shares (equivalent to 9.6% of DEM’s current shares outstanding)
- New Shares issued under the Placement will be issued under the Company’s existing placement capacity per LR 7.1 and will rank equally with existing DEM shares

Offer price

- New shares under the Placement will be issued at a price of A\$0.14 per share, representing a
 - 18.6% discount to the 5-day VWAP (Volume Weighted Average Price) to 25 July 2022

Joint Lead Managers

- Bell Potter Securities Limited and Blue Ocean Equities Pty Ltd are Joint Lead Managers and Bookrunners to the Placement

¹ Participation by major shareholder New Asia Investments will be subject to shareholder approval at an extraordinary general meeting

Expected Uses of Funds (A\$m)	A\$3m
Acquisition of the remaining 25% in De.mem-Geutec GmbH, taking the ownership to 100%	0.35
Funding of Build Own Operate opportunities	1.0
Future acquisitions and general working capital	1.45
Offer Costs	0.2
Total Uses	3.0

25% acquisition of De.mem-Geutec GmbH

- Key step for further expansion into the European market
- Following approx. 78% revenue growth of De.mem-Geutec from A\$ 1.8m prior to the acquisition in 2019, to A\$ 3.2m in CY2021
- Reasonable agreed-upon valuation of approx. A\$345k for 25% in De.mem-Geutec, only ~13% above the valuation paid for the initial transaction in 2019 (A\$ 915k for 75%)

Funding of Build Own Operate opportunities

- Targeting to enter into further BOO/BOOT contracts in Singapore and/or Australia
- Following the successful delivery on two key BOO/BOOT projects as reported in the June 2022 Quarterly Activities Report
- Intention to fund additional, larger Build, Own, Operate opportunities through non-dilutive debt instruments

Event	2022
Trading halt announced	Pre-market Tuesday, 26 July
Trading halt lifted, Placement Announcement and Appendix 3B	Pre-market Thursday, 28 July
Settlement of Placement proceeds and Appendix 2A	Tuesday, 2 August
Allotment of Placement shares	Wednesday, 3 August

Note: All dates are subject to change and are indicative only. The Company and Lead Manager reserves the right to vary these dates without prior notice.



1

Targeting first quarterly EBITDA break even by H1 CY2023

- Visible path to EBITDA break even, with first quarterly break even expected in H1 CY2023, predominantly driven by:
 - ❖ Revenue growth
 - ❖ 2 BOO projects previously awarded to De.mem generating revenues from July 2022
 - ❖ EBITDA contribution from the Stevco acquisition in April 2022
 - ❖ Reduction in exposure to lower margin projects

2

Growth of high margin recurring revenue segments, in particular specialty chemicals

- Growth of Capic specialty chemicals business from \$300k per month to nearly \$500k per month in revenues, since the Capic acquisition in April 2021
- Increasing pipeline of significant future opportunities for specialty chemicals supply

3

Regulatory certification of Graphene Oxide membrane technology and subsequent commercialisation into global markets

- National Sanitation Foundation (American) and WaterMark (Australian) regulatory product certification as basis for commercial launch expected in late CY2022
- Commercial launch into US and Australia expected immediately following the achievement of regulatory product certifications in late CY2022
- Concurrently exploring commercial launch into other countries (i.e. Singapore)

4

Continued uptake and expansion of unique Build, Own, Operate offering for industrial clients


- Continue to sign new contracts, with a strong pipeline for future execution
- Closing of loan facility to fund BOO schemes on a non-dilutive basis

5

Continued execution of accretive acquisitions at attractive valuations across highly fragmented markets



demem 



Andreas Kroell


Chief Executive Officer

De.mem Limited

investor@demem.com.sg

APPENDIX 1: DE.MEM TECH: BROAD APPLICATION RANGE

De.mem's hollow fibre membrane technology comes with a variety of pore sizes which can remove tiny contaminants including dyes, pesticides/herbicides, microplastics, solids, viruses, bacteria etc. in a simple process



De.mem Technology	Ultrafiltration		Nanofiltration	Graphene-Oxide Enhanced
Key Features	PES based hollow fibre Ultrafiltration membrane with Molecular Weight Cutoff (MWCO) of 100,000 Dalton (Da)	PVDF based hollow fibre Ultrafiltration membrane with MWCO of 300,000 – 500,000 Da	PES based hollow fibre Nanofiltration membrane with MWCO of 500-1,000 Da	Graphene-Oxide enhanced hollow fibre PES Ultrafiltration membrane
Technical Advantages	vs. conventional filtration: <ul style="list-style-type: none"> • Good flux • Low fouling • Operates under 1-2 bar pressure • High rejection of virus & bacteria • Narrow pore size distribution - higher purity for value-added products 	vs. conventional filtration: <ul style="list-style-type: none"> • High flux • Chlorine resistant • Operates under 1-3 bar pressure • Basis for further development (Membrane Bioreactor/MBR and oil resistant membrane tech) 	vs. conventional filtration: <ul style="list-style-type: none"> • High rejection of small molecules • No or only limited use of commodity type chemicals vs. Reverse Osmosis / flat sheet nanofiltration: <ul style="list-style-type: none"> • Operates under low pressure of ~2bar • Low fouling • Simple flush procedure for cleaning • No spacers needed • No or only simple pre-treatment (depends on application) 	vs. conventional filtration: <ul style="list-style-type: none"> • Significantly higher flux / throughput • Low fouling • Potentially, higher rejection of certain contaminants i.e. bacteria (currently being verified)
Commercial Advantages	vs. conventional applications: <ul style="list-style-type: none"> • Well proven and cost effective Ultrafiltration membrane • Applications in drinking water production, waste water treatment, food & beverages, RO pre treatment 	vs. conventional applications: <ul style="list-style-type: none"> • High stability • Extended use for applications in biological & oily waste water treatment upcoming 	vs. conventional filtration: <ul style="list-style-type: none"> • High quality filtration vs. Reverse Osmosis / flat sheet nanofiltration: <ul style="list-style-type: none"> • Reduces energy consumption • Easy to clean and maintain • Easy to operate • Small footprint • Low Capex • Environmentally friendly 	vs. conventional applications: <ul style="list-style-type: none"> • Reduced operating cost • Reduced cartridge size / footprint